Compare CVV & NXL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVV | NXL |
|---|---|---|
| Founded | 1982 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 21.9M | 18.6M |
| IPO Year | N/A | 2022 |
| Metric | CVV | NXL |
|---|---|---|
| Price | $4.11 | $0.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $5.00 |
| AVG Volume (30 Days) | 27.1K | ★ 211.3K |
| Earning Date | 11-10-2025 | 11-14-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $28,251,000.00 | $156,931.00 |
| Revenue This Year | N/A | $38.28 |
| Revenue Next Year | N/A | $185.71 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 19.85 | N/A |
| 52 Week Low | $2.46 | $0.54 |
| 52 Week High | $4.80 | $3.87 |
| Indicator | CVV | NXL |
|---|---|---|
| Relative Strength Index (RSI) | 75.92 | 44.98 |
| Support Level | $3.03 | $0.54 |
| Resistance Level | $3.99 | $0.64 |
| Average True Range (ATR) | 0.20 | 0.07 |
| MACD | 0.11 | 0.02 |
| Stochastic Oscillator | 82.38 | 71.28 |
CVD Equipment Corp is engaged in the manufacturing of chemical vapor deposition equipment, customized gas control systems, the manufacturing of process equipment suitable for the synthesis of a variety of one-dimensional nanostructures and nanomaterials and a line of furnaces, all of which are used to produce semiconductors and other electronic components. The company operates through the segments of CVD Equipment, CVD materials, and Stainless Design Concepts, MesoScribe. It generates maximum revenue from the CVD Equipment segment. The CVD Equipment segment manufactures and sells chemical vapor deposition, physical vapor transport, and similar equipment. Company operates in USA, North America, Europe, Middle East and Africa, and Asia-Pacific.
Nexalin Technology Inc designs and develops neurostimulation products to uniquely and effectively help combat the ongoing mental health epidemic. The company has developed an easy-to-administer medical device referred to as Generation 1 or Gen-1 that utilizes bioelectronic medical technology to treat anxiety and insomnia, without the need for drugs or psychotherapy. Its original Gen-1 devices are cranial electrotherapy stimulation (CES) devices that emit waveform at 4 milliamps during treatment and are presently classified by the U.S. Food and Drug Administration (FDA) as a Class II device.